Exploring Your Options for NRG1 Fusion-Positive Cancer

Participating a clinical trial for NRG1 fusion-positive cancer could be an option for you.

Compliance and Security Certifications

[EN] Ads Landing Pages - United States & Canada - English
Let's Explore Your Options

Your Birthday


By filling out this form, you're consenting only to release your medical records. You're not agreeing to participate in clinical trials yet.

Massive Bio has onboarded over 160,000 cancer patients to find their clinical trial

If your doctor has told you that your cancer is positive for the NRG1 fusion, it means that an important gene has fused with another, potentially fueling the growth of various cancers. The NRG1 gene is responsible for producing a protein called neuregulin 1, which plays a crucial role in the normal development of the cardiovascular and nervous systems. However, in rare cases, a gene can merge with another, forming “fusion genes” that may create proteins associated with cancer progression.

NRG1 Biomarker in Cancer

Several targeted drugs for NRG1 fusions are in advanced stages of development, while others are currently recruiting patients for clinical studies. These medications are designed to address different types of tumors that have spread, or metastasized, throughout the body.

For example, if you have metastatic gastric cancer, have considered enrolling in a pancreatic cancer clinical study, or have another form of solid tumor that has spread, you may be eligible for an innovative approach designed to combat NRG1 fusion-driven tumors.

Cancer is an unfortunate reality that touches most of us at some point in our lives. If you or a loved one has cancer, you may have heard or read that clinical trials could offer access to innovative new options. But what exactly is a clinical trial? In this video, Massive Bio co-founder Arturo Loaiza-Bonilla, MD, explains how clinical trials work, what to expect if you enroll in one, and why a clinical trial can be an important option for many cancer patients.

Exploring Your Clinical Trial Options for NRG1 Fusion-Positive Cancer

If your doctor has told you that your cancer is positive for the NRG1 fusion, it means that an important gene has fused with another, potentially fueling the growth of various cancers. The NRG1 gene is responsible for producing a protein called neuregulin 1, which plays a crucial role in the normal development of the cardiovascular and nervous systems. However, in rare cases, a gene can merge with another, forming “fusion genes” that may create proteins associated with cancer progression.

NRG1 Biomarker in Cancer

Several targeted drugs for NRG1 fusions are in advanced stages of development, while others are currently recruiting patients for clinical studies. These medications are designed to address different types of tumors that have spread, or metastasized, throughout the body.

For example, if you have metastatic gastric cancer, have considered enrolling in a pancreatic cancer clinical study, or have another form of solid tumor that has spread, you may be eligible for an innovative approach designed to combat NRG1 fusion-driven tumors.

Dr. Arturo explains:

What Are Clinical Trials?

Cancer is an unfortunate reality that touches most of us at some point in our lives. If you or a loved one has cancer, you may have heard or read that clinical trials could offer access to innovative new options. But what exactly is a clinical trial? In this video, Massive Bio co-founder Arturo Loaiza-Bonilla, MD, explains how clinical trials work, what to expect if you enroll in one, and why a clinical trial can be an important option for many cancer patients.

How Massive Bio Helps Patients With NRG1 Fusion-Positive ?
1
Consent Signed

Fill out our contact form and sign our consent form

2
Data Collection

We collect your medical records securely

3
Pre Screening

Our expert nurses check clinical trials and contact you

4
Concierge Services

We support you with appointments, travel, and accommodation

Let’s explore your options and bring new hope to your journey.

We offer a quick, easy and free way to find NRG1 Fusion-Positive cancer clinical research opportunities for patients like you. With our unique clinical trial matching system (CTMS) and team specialized in oncology, we can rapidly match you to a clinical research study for those diagnosed with NRG1 Fusion-Positive cancer.

[EN] Ads Landing Pages - United States & Canada - English
Let's Explore Your Options

Your Birthday


By filling out this form, you're consenting only to release your medical records. You're not agreeing to participate in clinical trials yet.
Frequently asked questions

To enroll in clinical trial, you must meet highly specific criteria that’s established by the researchers who are conducting the investigation. That includes detailed information about type of cancer, treatment history, response to treatment, and other data that is collected in medical records.

If you are being treated for cancer or any other disease, your doctor should have a complete record of your medical care, including specific information about what form of the disease you have and what treatments you have received. Your patient relations coordinator will contact you and inform you about the details.

Massive Bio provides its services to the patients and their doctors at no cost—you won’t have to pay anything to receive a clinical-research matching report. There are no hidden costs involved.

Massive Bio strictly adheres to all HIPAA guidelines and international regulations focused on maintaining your privacy. We take extra measures to secure your personal information, ensuring it is protected beyond the mandatory requirements.

Your doctor may know of a clinical research study being conducted in your area that’s recruiting participants and is right for you. However, Massive Bio uses its artificial intelligence powered platform to match patients to clinical research studies that give you the best chance of a positive outcome and are being conducted in a geographical location that makes sense for you.

Yes, Massive Bio keeps your doctor up to date on your status throughout your participation.